Pamidronat Onkovis (Pamidronate Disodium)

Pamidronate Disodium, the active ingredient in Pamidronat Onkovis, is a bis‑bisphosphonate presented as a sterile injectable solution for intravenous use. It is employed in the management of bone‑related disorders such as hypercalcaemia of malignancy, Paget’s disease and bone metastases, primarily in adult patients. GNH USA supplies Pamidronat Onkovis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamidronate Disodium is a bis‑bisphosphonate that acts on disorders of bone turnover and calcium metabolism. - Hypercalcaemia of malignancy: helps lower elevated serum calcium levels. - Paget’s disease of bone: reduces abnormal bone remodeling and pain. - Bone metastases from solid tumours: decreases skeletal‑related events and bone pain. - Osteolysis associated with multiple myeloma: limits bone loss and fracture risk.

Adverse reactions to pamidronate may vary in frequency and severity.

Common Side Effects: - Flu-like symptoms such as fever, chills, or myalgia. - Transient elevation of serum creatinine. - Nausea or vomiting. - Mild electrolyte disturbances (e.g., hypocalcaemia). - Injection‑site discomfort or erythema.

Serious or Rare Side Effects: - Acute renal failure or significant renal impairment. - Severe hypocalcaemia with tetany or seizures. - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Anaphylactic or severe hypersensitivity reactions.

When using Pamidronat Onkovis, clinicians should assess renal function and calcium status, and monitor patients for potential adverse events. - Renal function: evaluate baseline creatinine and adjust use in renal impairment. - Calcium levels: correct hypocalcaemia before initiating therapy. - Concomitant nephrotoxic drugs: avoid or use with caution. - Dental health: perform dental examination before treatment to reduce ONJ risk. - Pregnancy and lactation: avoid use unless clearly indicated and benefits outweigh risks. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Pamidronate may interact with several co‑administered medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Concurrent high‑dose NSAIDs or COX‑2 inhibitors: increase risk of renal toxicity. - Aminoglycoside antibiotics: additive nephrotoxic potential.

Moderate Interactions (Monitor Closely): - Calcium‑containing supplements or antacids: may reduce pamidronate absorption if given too close in time. - Loop diuretics: can exacerbate electrolyte disturbances. - Vitamin D analogues: require careful monitoring of calcium levels. - Chemotherapy agents (e.g., cis‑platin): monitor renal function closely.